Subphenotypes in Patients with Acute Respiratory Distress Syndrome Treated with High-flow Oxygen

Overview

Journal Crit Care

Specialty Critical Care

Date 2023 Nov 2

PMID 37915062

Authors

Pierre-Louis Blot

Benjamin G Chousterman

Manel Santafe

Jerome Cartailler

Andres Pacheco

Monica Magret

Joan R Masclans

Antoni Artigas

Oriol Roca

Marina Garcia-de-Acilu

Affiliations

Soon will be listed here.

Abstract

Background: Acute respiratory distress syndrome (ARDS) subphenotypes differ in outcomes and treatment responses. Subphenotypes in high-flow nasal oxygen (HFNO)-treated ARDS patients have not been investigated.

Objectives: To identify biological subphenotypes in HFNO-treated ARDS patients.

Methods: Secondary analysis of a prospective multicenter observational study including ARDS patients supported with HFNO. Plasma inflammation markers (interleukin [IL]-6, IL-8, and IL-33 and soluble suppression of tumorigenicity-2 [sST2]) and lung epithelial (receptor for advanced glycation end products [RAGE] and surfactant protein D [SP-D]) and endothelial (angiopoietin-2 [Ang-2]) injury were measured. These biomarkers and bicarbonate were used in K-means cluster analysis to identify subphenotypes. Logistic regression was performed on biomarker combinations to predict clustering. We chose the model with the best AUROC and the lowest number of variables. This model was used to describe the HAIS (High-flow ARDS Inflammatory Subphenotype) score.

Results: Among 41 HFNO patients, two subphenotypes were identified. Hyperinflammatory subphenotype (n = 17) showed higher biomarker levels than hypoinflammatory (n = 24). Despite similar baseline characteristics, the hyperinflammatory subphenotype had higher 60-day mortality (47 vs 8.3% p = 0.014) and longer ICU length of stay (22.0 days [18.0-30.0] vs 39.5 [25.5-60.0], p = 0.034). The HAIS score, based on IL-8 and sST2, accurately distinguished subphenotypes (AUROC 0.96 [95%CI: 0.90-1.00]). A HAIS score ≥ 7.45 was predictor of hyperinflammatory subphenotype.

Conclusion: ARDS patients treated with HFNO exhibit two biological subphenotypes that have similar clinical characteristics, but hyperinflammatory patients have worse outcomes. The HAIS score may identify patients with hyperinflammatory subphenotype and might be used for enrichment strategies in future clinical trials.

References

Roca O, Riera J, Torres F, Masclans J . High-flow oxygen therapy in acute respiratory failure. Respir Care. 2010; 55(4):408-13. View

Youden W . Index for rating diagnostic tests. Cancer. 1950; 3(1):32-5. DOI: 10.1002/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3. View

Grasselli G, Calfee C, Camporota L, Poole D, Amato M, Antonelli M . ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies. Intensive Care Med. 2023; 49(7):727-759. PMC: 10354163. DOI: 10.1007/s00134-023-07050-7. View

Garcia-de-Acilu M, Marin-Corral J, Vazquez A, Ruano L, Magret M, Ferrer R . Hypoxemic Patients With Bilateral Infiltrates Treated With High-Flow Nasal Cannula Present a Similar Pattern of Biomarkers of Inflammation and Injury to Acute Respiratory Distress Syndrome Patients. Crit Care Med. 2017; 45(11):1845-1853. DOI: 10.1097/CCM.0000000000002647. View

Kangelaris K, Ware L, Wang C, Janz D, Zhuo H, Matthay M . Timing of Intubation and Clinical Outcomes in Adults With Acute Respiratory Distress Syndrome. Crit Care Med. 2015; 44(1):120-9. PMC: 4774861. DOI: 10.1097/CCM.0000000000001359. View

Shankar-Hari M, Fan E, Ferguson N . Acute respiratory distress syndrome (ARDS) phenotyping. Intensive Care Med. 2018; 45(4):516-519. DOI: 10.1007/s00134-018-5480-6. View

Sinha P, Furfaro D, Cummings M, Abrams D, Delucchi K, Maddali M . Latent Class Analysis Reveals COVID-19-related Acute Respiratory Distress Syndrome Subgroups with Differential Responses to Corticosteroids. Am J Respir Crit Care Med. 2021; 204(11):1274-1285. PMC: 8786071. DOI: 10.1164/rccm.202105-1302OC. View

Martinez-Gonzalez I, Roca O, Masclans J, Moreno R, Salcedo M, Baekelandt V . Human mesenchymal stem cells overexpressing the IL-33 antagonist soluble IL-1 receptor-like-1 attenuate endotoxin-induced acute lung injury. Am J Respir Cell Mol Biol. 2013; 49(4):552-62. DOI: 10.1165/rcmb.2012-0406OC. View

Sinha P, Delucchi K, Thompson B, McAuley D, Matthay M, Calfee C . Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study. Intensive Care Med. 2018; 44(11):1859-1869. PMC: 6317524. DOI: 10.1007/s00134-018-5378-3. View

10.

Matthay M, Arabi Y, Arroliga A, Bernard G, Bersten A, Brochard L . A New Global Definition of Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2023; 209(1):37-47. PMC: 10870872. DOI: 10.1164/rccm.202303-0558WS. View

11.

Ware L, Koyama T, Zhao Z, Janz D, Wickersham N, Bernard G . Biomarkers of lung epithelial injury and inflammation distinguish severe sepsis patients with acute respiratory distress syndrome. Crit Care. 2013; 17(5):R253. PMC: 4056313. DOI: 10.1186/cc13080. View

12.

Bos L, Schouten L, van Vught L, Wiewel M, Ong D, Cremer O . Identification and validation of distinct biological phenotypes in patients with acute respiratory distress syndrome by cluster analysis. Thorax. 2017; 72(10):876-883. PMC: 5964254. DOI: 10.1136/thoraxjnl-2016-209719. View

13.

van der Ven F, Valk C, Blok S, Brouwer M, Go D, Lokhorst A . Broadening the Berlin definition of ARDS to patients receiving high-flow nasal oxygen: an observational study in patients with acute hypoxemic respiratory failure due to COVID-19. Ann Intensive Care. 2023; 13(1):64. PMC: 10349031. DOI: 10.1186/s13613-023-01161-6. View

14.

Famous K, Delucchi K, Ware L, Kangelaris K, Liu K, Thompson B . Acute Respiratory Distress Syndrome Subphenotypes Respond Differently to Randomized Fluid Management Strategy. Am J Respir Crit Care Med. 2016; 195(3):331-338. PMC: 5328179. DOI: 10.1164/rccm.201603-0645OC. View

15.

Agrawal A, Matthay M, Kangelaris K, Stein J, Chu J, Imp B . Plasma angiopoietin-2 predicts the onset of acute lung injury in critically ill patients. Am J Respir Crit Care Med. 2013; 187(7):736-42. PMC: 3678110. DOI: 10.1164/rccm.201208-1460OC. View

16.

Jabaudon M, Futier E, Roszyk L, Chalus E, Guerin R, Petit A . Soluble form of the receptor for advanced glycation end products is a marker of acute lung injury but not of severe sepsis in critically ill patients. Crit Care Med. 2011; 39(3):480-8. DOI: 10.1097/CCM.0b013e318206b3ca. View

17.

Parsons P, Eisner M, Thompson B, Matthay M, Ancukiewicz M, Bernard G . Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury. Crit Care Med. 2005; 33(1):1-6. DOI: 10.1097/01.ccm.0000149854.61192.dc. View

18.

Calfee C, Delucchi K, Sinha P, Matthay M, Hackett J, Shankar-Hari M . Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. Lancet Respir Med. 2018; 6(9):691-698. PMC: 6201750. DOI: 10.1016/S2213-2600(18)30177-2. View

19.

Rochwerg B, Einav S, Chaudhuri D, Mancebo J, Mauri T, Helviz Y . The role for high flow nasal cannula as a respiratory support strategy in adults: a clinical practice guideline. Intensive Care Med. 2020; 46(12):2226-2237. PMC: 7670292. DOI: 10.1007/s00134-020-06312-y. View

20.

Delucchi K, Famous K, Ware L, Parsons P, Thompson B, Calfee C . Stability of ARDS subphenotypes over time in two randomised controlled trials. Thorax. 2018; 73(5):439-445. PMC: 6497167. DOI: 10.1136/thoraxjnl-2017-211090. View